NCT06201741View on ClinicalTrials.gov

A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled ZT-111 in Patients With Metastatic Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

June 30, 2024

Conditions
Prostate Specific Membrane Antigen Positive Metastatic Prostate Cancer
Interventions
RADIATION

[131I]/[18F]/[68Ga]ZT-111

\[131I\]/\[18F\]/\[68Ga\]ZT-111, single dose

Trial Locations (1)

Unknown

RECRUITING

Huashan Hospital, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER